The Swiss MR-in-RT Symposium 2026 brings together international experts to discuss current developments and future perspectives in MR-guided radiotherapy. From adaptive treatment concepts and workflow integration to AI-supported innovation and translational research, the symposium provides concise insights into how MR technologies are advancing precision radiation oncology.
Date
13 Nov 2026
Time
08:45 - 16:00
Type
Hybrid
Location
University Hospital Zurich
Lecture hall
Grosser Hörsaal Path / D22
Magnetic Resonance (MR) in radiation therapy is redefining precision oncology by enabling superior soft-tissue imaging, adaptive treatment, and real-time monitoring. Its clinical impact is increasingly evident across tumor sites, while technological advances—from functional low-field MR to AI-driven planning—are unlocking new opportunities for personalized care.
The Swiss MR-in-RT Symposium 2026 convenes leading experts to explore the clinical applications, technological innovations, and implementation challenges of MR-guided radiation therapy. Participants will gain practical perspectives from early adopters, learn about evolving adaptive treatment strategies, and discuss future directions in workflow optimization, sustainability, and clinical research.
Join us in person at the University Hospital Zurich or online to engage with the latest advances in MR-guided radiation oncology.
Registration
Please register by November 6, 2026.
13.11.2026
08:45
Registration, Coffee and Gipfeli
09:15
Welcome & Introduction
Sebastian M. Christ, University Hospital Zurich, Switzerland
Session 1: Clinical Impact of MR-in-RT
Thomas Zilli, Ente Ospedaliero Cantonale, Switzerland and
Daniel Aebersold, Inselspital, University Hospital Bern, Switzerland
09:30
MR-enhanced ART: What is the Clinical Evidence to date?
Juliane Hörner-Rieber, University Hospital Düsseldorf, Germany
09:50
MR-enhanced ART in the Thorax: Managing Motion, Margins, and Risk
Fabian Weykamp, University Hospital Heidelberg, Germany
10:10
MR-adaptive ART in the Head & Neck Space: Results of the MARTHA Study
Panagiotis Balermpas, University Hospital Zurich, Switzerland
10:30
How to design the next generation of MR-enhanced ART clinical trials
Michael Chuong, Wertheim Cancer Institute, Florida, USA
10:50
Coffee Break
Session 2: Implementing MR-in-RT
Moderated by Jakob Liermann, Heidelberg University Hospital, Germany and
Christoph Bert, University Hospital Erlangen / FAU Erlangen-Nürnberg, Germany
11:20
Implementing MR-in-RT at Scale: Lessons from Early Adopters
Martin Fast, University Medical Center Utrecht, The Netherlands
11:40
Dose Accumulation in ART: Are We Measuring What We Think We Are?
Francesca Albertini, Paul Scherrer Institut PSI, Aargau, Switzerland
12:00
Workflow, Throughput, Economics: Can MR-enhanced ART be sustainable?
Tobias Finazzi, Kantonsspital Baden, Switzerland
12:20
Lunch Break
Session 3: Technology, AI & Advanced Imaging
Moderated by Oliver Riesterer, Kantonsspital Aarau, Switzerland and
Stephanie Corradini, LMU-Hospital Munich, Germany
13:20
Planning MR, MR-Only and MR-First Planning: Technology is ready – are we?
Riccardo Dal Bello, University Hospital Zurich, Switzerland
13:40
Functional low-field MR, Radiomics, AI: What can we translate into clinics?
Jessica Scholey, University of California San Francisco, California, USA
Session 4: Podium Discussion
Moderated by Sebastian M. Christ, University Hospital Zurich, Switzerland
14:00
Podium Discussion: “Are we over-engineering RT through the use of MR?”
Michael Chuong, Wertheim Cancer Institute, Florida, USA
Stefanie Corradini, LMU-Hospital Munich, Germany
Juliane Hörner-Rieber, University Hospital Düsseldorf, Germany
Jessica Scholey, University of California San Francisco, California, USA
14:45
Closing Remarks
Sebastian M. Christ, University Hospital Zurich, Switzerland
15:00
Coffee Break
Session 5: Accela: A New Generation of Linear Accelerator Technology
Moderated by Stephanie Tanadini-Lang, University Hospital Zurich, Switzerland
16:30
Closing Apéro